The landscape of cell and gene therapies (CGTs) is undergoing a significant transformation, expanding beyond oncology into the treatment of autoimmune diseases.
This shift is driven by the success of chimeric antigen receptor (CAR)-T therapies in hematologic malignancies, the growing unmet need in autoimmune disorders and advancements in immunomodulatory techniques such as regulatory T cells (Tregs) and gene editing technologies like CRISPR. Additionally, regulatory agencies and biopharmaceutical companies are increasingly investing in this field, recognizing its potential for widespread clinical impact.
With over 80 recognized autoimmune diseases affecting millions globally, existing treatments rely on symptom management rather than curative approaches. The application of CGTs offers a promising new frontier for restoring immune tolerance and achieving long-term remission; however, the unique challenges such as disease complexity, immune system risks, scalability and cost considerations must be carefully navigated.
The successful implementation of CGTs for autoimmune diseases requires an approach that integrates expertise in immunology, genetic and cellular engineering, and regulatory compliance for living therapies. Patient-physician engagement and education are also critical for adoption and accessibility.
This webinar will explore the key drivers behind the transition from oncology to autoimmune and the essential considerations needed to advance CGTs in autoimmune disease treatment. Through case studies, scientific breakthroughs and industry insights, this webinar will provide a comprehensive overview of the shift in clinical research priorities and the future of CGTs in autoimmune disease treatment.
Register for this webinar to explore the exciting evolution in regenerative medicine and immunotherapy.
Speakers
Desmond Cabrera, Vice President, Global Head, Cell and Gene Therapy, Allucent
Desmond Cabrera is a seasoned global operations leader with extensive experience in biotechnology and pharmaceuticals. He specializes in cell and gene therapy and has led clinical trials across multiple therapeutic areas. As VP, Head of Global Operations for a mid-sized global CRO, Desmond oversees global project management teams, financial planning and milestone delivery.
His expertise in multinational team leadership, process optimization and strategic partnerships consistently drives operational excellence and customer satisfaction. Desmond’s track record in advancing clinical development and executing high-stakes negotiations has been instrumental in achieving corporate goals and ensuring long-term success.
Message Presenter
Dr. Brian Abbott, MD, Executive Medical Director, Therapeutic Area Medical Lead, Oncology/Hematology, Allucent
Dr. Brian Abbott, MD, is an expert in hematology, oncology and biomedical research, specializing in clinical trial strategy and medical monitoring. As Executive Medical Director at Allucent, he provides strategic guidance on clinical trials. He previously held leadership roles at ICON plc, Myriad Genetics and Caris Life Sciences.
Before transitioning to research, Dr. Abbott focused on hematologic malignancies, BMT and medical oncology, serving on the faculty at the University of Colorado and St. Jude Children’s Research Hospital. He holds an MD, MBA and MS in Finance and is board-certified in Hematology/Oncology, Pediatrics and Hospice and Palliative Medicine.
Message Presenter
Stephanie Stempf, Project Director, Global Project Leadership, Clinical Project Management, Allucent
Stephanie Stempf, a Project Director specializing in Cell and Gene Therapy at Allucent, has over 15 years of clinical research experience. She oversees clinical trials, ensuring client satisfaction, timelines, and budgets while managing technical and operational aspects. Beginning in oncology at the site level, she advanced to clinical trial lead and has worked in project management since 2012. With expertise in 75+ studies across Phases I-III, oncology, immuno-oncology, and advanced therapies, she has extensive PK/PD and tumor tissue collection experience. Previously, she was a Program Manager at Tempus Labs. Stephanie holds a Microbiology degree from Michigan State University.
Message PresenterWho Should Attend?
This webinar will appeal to VPs, Directors, Managers and Heads involved in:
- Research and Development (R&D)
- Clinical Project Management/Trial Oversight
- Clinical Operations/Clinical Research
- Medical Affairs/Medical Writing/Pharmacovigilance
- Biostatistics and Data Science
- Regulatory Affairs/Strategy
- Chief Medical Officers (CMOs) and CEOs of small and medium-sized biotech/pharmaceutical companies
What You Will Learn
In this webinar, the featured speakers will discuss and cover:
- The trial design benefits and challenges presented by basket and umbrella trials
- Strategies to standardize endpoints and improve the objectivity of clinical assessments
- Insights into adaptive medical monitoring strategies crucial for supporting master protocol frameworks
- Best practices for the effective operational management of multi-arm clinical trials
- How employing these advanced trial designs can significantly accelerate the development of therapies for rare diseases
Xtalks Partner
Allucent
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account